Immune Thrombocytopenia Purpura Overview

Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly.

“Immune Thrombocytopenia Purpura Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Immune Thrombocytopenia Purpura Market.

The Immune Thrombocytopenia Purpura Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Immune Thrombocytopenia Purpura Pipeline Report:

• Companies across the globe are diligently working toward developing novel Immune Thrombocytopenia Purpura treatment therapies with a considerable amount of success over the years. Immune Thrombocytopenia Purpura Key players such as – Merck Sharp & Dohme LLC, Symphogen A/S, Rigel Pharmaceuticals, GlaxoSmithKline, Octapharma, Amgen, GlaxoSmithKline, Principia Biopharma, 3SBio Inc, Amgen Inc, Biotest AG, GC Pharma, HanAll Biopharma Co Ltd, Hutchison MediPharma Ltd, Jiangsu Hengrui Medicine Co Ltd, Novartis AG, Swedish Orphan Biovitrum AB, and others, are developing therapies for the Immune Thrombocytopenia Purpura treatment 
• Immune Thrombocytopenia Purpura Emerging therapies such as – MK-8723, Sym001, Fostamatinib disodium, LGD-4665, Octagam, Romiplostim, Eltrombopag, PRN1008, and others are expected to have a significant impact on the Immune Thrombocytopenia Purpura market in the coming years.   
• In November 2020, Rilzabrutinib received Fast Track Designation (FTD) by US FDA and is currently under a Phase 3 study for ITP. Rilzabrutinib received an orphan drug designation from the FDA for the treatment of Immune Thrombocytopenia Purpura in October 2018
• Rozanolixizumab has received orphan drug designation by the USFDA on 30 April 2018 and by the European Commission on 11 January 2019 for its use in the ITP market
• Patent expiries of already approved drugs such as Nplate and Promacta will give the freeway to generics and biosimilars in the Immune Thrombocytopenia Purpura market.

Route of Administration

Immune Thrombocytopenia Purpura pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Immune Thrombocytopenia Purpura Pipeline Therapeutics Assessment

• Immune Thrombocytopenia Purpura Pipeline Therapeutics Assessment
• Immune Thrombocytopenia Purpura Assessment by Product Type
• Immune Thrombocytopenia Purpura By Stage and Product Type
• Immune Thrombocytopenia Purpura Assessment by Route of Administration
• Immune Thrombocytopenia Purpura By Stage and Route of Administration
• Immune Thrombocytopenia Purpura Assessment by Molecule Type
• Immune Thrombocytopenia Purpura by Stage and Molecule Type

DelveInsight’s Immune Thrombocytopenia Purpura Report covers around 20+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Immune Thrombocytopenia Purpura Therapeutics Market include:

Key companies developing therapies for Immune Thrombocytopenia Purpura are – 3SBio Inc, Amgen Inc, Biotest AG, GC Pharma, HanAll Biopharma Co Ltd, Hutchison MediPharma Ltd, Jiangsu Hengrui Medicine Co Ltd, Novartis AG, Rigel Pharmaceuticals Inc, and Swedish Orphan Biovitrum AB, and others.

Emerging Immune Thrombocytopenia Purpura Drugs Under Different Phases of Clinical Development Include:

• MK-8723: Merck Sharp & Dohme LLC
• Sym001: Symphogen A/S
• Fostamatinib disodium: Rigel Pharmaceuticals
• LGD-4665: GlaxoSmithKline
• Octagam: Octapharma
• Rozanolixizumab: UCB
• Romiplostim: Amgen
• Mezagitamab: Takeda
• Eltrombopag: GlaxoSmithKline
• PRN1008: Principia Biopharma

Get a Free Sample PDF Report to know more about Immune Thrombocytopenia Purpura Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/immune-thrombocytopenic-purpura-pipeline-insight

Immune Thrombocytopenia Purpura Pipeline Analysis:

The Immune Thrombocytopenia Purpura pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Immune Thrombocytopenia Purpura with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Immune Thrombocytopenia Purpura Treatment.
• Immune Thrombocytopenia Purpura key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Immune Thrombocytopenia Purpura Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Immune Thrombocytopenia Purpura market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Immune Thrombocytopenia Purpura product details are provided in the report. Download the Immune Thrombocytopenia Purpura pipeline report to learn more about the emerging Immune Thrombocytopenia Purpura therapies

Scope of Immune Thrombocytopenia Purpura Pipeline Drug Insight    

• Coverage: Global
• Key Immune Thrombocytopenia Purpura Companies: Merck Sharp & Dohme LLC, Symphogen A/S, Rigel Pharmaceuticals, GlaxoSmithKline, Octapharma, Amgen, GlaxoSmithKline, Principia Biopharma, 3SBio Inc, Amgen Inc, Biotest AG, GC Pharma, HanAll Biopharma Co Ltd, Hutchison MediPharma Ltd, Jiangsu Hengrui Medicine Co Ltd, Novartis AG, Swedish Orphan Biovitrum AB, and others
• Key Immune Thrombocytopenia Purpura Therapies: MK-8723, Sym001, Fostamatinib disodium, LGD-4665, Octagam, Romiplostim, Eltrombopag, PRN1008, and others
• Immune Thrombocytopenia Purpura Therapeutic Assessment: Immune Thrombocytopenia Purpura current marketed and Immune Thrombocytopenia Purpura emerging therapies
• Immune Thrombocytopenia Purpura Market Dynamics: Immune Thrombocytopenia Purpura market drivers and Immune Thrombocytopenia Purpura market barriers 

Request for Sample PDF Report for Immune Thrombocytopenia Purpura Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Immune Thrombocytopenia Purpura drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting